Clinical Trial Update: Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of a first-in-human mosquito saliva peptide vaccine; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mosquito-borne Disease

Drugs mentioned

• Mosquito saliva peptide vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Mosquito-Borne Disease | Phase 1 | Status: COMPLETED | Results posted: 2020-08-03